IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population

OncoImmunology

Volumn 7, Issue 1, 2018, Pages

  Barjon, Clément ^a   Michaud, Henri Alexandre ^a,d   Fages, Angeline ^a   Dejou, Cécile ^b   Zampieri, Alexandre ^a   They, Laetitia ^a   Gennetier, Aurélie ^a   Sanchez, Françoise ^a   Gros, Laurent ^a   Eliaou, Jean François ^a,b,c   Bonnefoy, Nathalie ^a,d   Lafont, Virginie ^a,c  

^a INSERM   (France)

^b OREGA Biotech   (France)

^c HÔPITAL SAINT ELOI   (France)

^d NONE

Author keywords

adenosine; CD73; IL 10; IL 21; regulatory functions; tumor microenvironment; T cells

Indexed keywords

EID: 85030567889     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1379642     Document Type: Article

References (42)

1. O'Brien RL, Roark CL, Born WK. IL-17-producing gammadelta T cells. Eur J Immunol. 2009;39:662-6. doi:10.1002/eji.200839120. PMID:19283718
2. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10:467-78. doi:10.1038/nri2781. PMID:20539306
3. Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annual Rev Immunol. 2000;18:975-1026. doi:10.1146/annurev.immunol.18.1.975.
4. Hintz M, Reichenberg A, Altincicek B, Bahr U, Gschwind RM, Kollas AK, Beck E, Wiesner J, Eberl M, Jomaa H. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in Escherichia coli. FEBS Letters. 2001;509:317-22. doi:10.1016/S0014-5793(01)03191-X. PMID:11741609
5. Altincicek B, Moll J, Campos N, Foerster G, Beck E, Hoeffler JF, Grosdemange-Billiard C, Rodríguez-Concepción M, Rohmer M, Boronat A, et al. Cutting edge: human gamma delta T cells are activated by intermediates of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis. J Immunol. 2001;166:3655-8. doi:10.4049/jimmunol.166.6.3655. PMID:11238603
6. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163-8. doi:10.1084/jem.20021500. PMID:12538656
7. Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opinion Immunol. 2006;18:539-46. doi:10.1016/j.coi.2006.07.002.
8. Riganti C, Massaia M, Davey MS, Eberl M. Human gammadelta T-cell responses in infection and immunotherapy: common mechanisms, common mediators? Eur J Immunol. 2012;42:1668-76. doi:10.1002/eji.201242492. PMID:22806069
9. Catros V, Toutirais O, Bouet F, Cabillic F, Desille M, Fournie JJ. Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes. Med Sci. 2010;26:185-91.
10. Buccheri S, Guggino G, Caccamo N, Li Donni P, Dieli F. Efficacy and safety of gammadeltaT cell-based tumor immunotherapy: a meta-analysis. J Biol Regulators Homeostatic Agents. 2014;28:81-90.
11. Gomes AQ, Martins DS, Silva-Santos B. Targeting gammadelta T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res. 2010;70:10024-7. doi:10.1158/0008-5472.CAN-10-3236. PMID:21159627
12. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67:7450-7. doi:10.1158/0008-5472.CAN-07-0199. PMID:17671215
13. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 2010;161:290-7. PMID:20491785
14. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102:200-6. doi:10.1182/blood-2002-12-3665. PMID:12623838
15. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, et al. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345-8. doi:10.1038/nature14282. PMID:25822788
16. Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, Shi L, Wu D, Dong C, Liu H. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 2014;74:1969-82. doi:10.1158/0008-5472.CAN-13-2534. PMID:24525743
17. Rei M, Goncalves-Sousa N, Lanca T, Thompson RG, Mensurado S, Balkwill FR, Kulbe H, Pennington DJ, Silva-Santos B. Murine CD27(-) Vgamma6(+) gammadelta T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc Natl Acad Sci USA. 2014;111:E3562-70. doi:10.1073/pnas.1403424111. PMID:25114209
18. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, et al. gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 2014;40:785-800. doi:10.1016/j.immuni.2014.03.013. PMID:24816404
19. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity. 2007;27:334-48. doi:10.1016/j.immuni.2007.05.020. PMID:17656116
20. Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G, Barilla R, Torres-Hernandez A, Hundeyin M, Mani VR, et al. gammadelta T Cells support pancreatic oncogenesis by restraining alphabeta T cell activation. Cell. 2016;166:1485-99 e15. doi:10.1016/j.cell.2016.07.046.
21. Croce M, Rigo V, Ferrini S. IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res. 2015;2015:696578. doi:10.1155/2015/696578. PMID:25961061
22. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annual Rev Immunol. 2008;26:57-79. doi:10.1146/annurev.immunol.26.021607.090316.
23. Leonard WJ, Wan CK. IL-21 signaling in immunity. F1000Research 2016; 5:224–234. doi:10.12688/f1000research.7634.1. PMID:26966515
24. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57-63. doi:10.1038/35040504. PMID:11081504
25. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201:139-48. doi:10.1084/jem.20041057. PMID:15630141
26. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, Smyth MJ, Godfrey DI. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol. 2007;178:2827-34. doi:10.4049/jimmunol.178.5.2827. PMID:17312126
27. Fantini MC, Rizzo A, Fina D, Caruso R, Becker C, Neurath MF, Macdonald TT, Pallone F, Monteleone G. IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. European J Immunol. 2007;37:3155-63. doi:10.1002/eji.200737766.
28. Lindner S, Dahlke K, Sontheimer K, Hagn M, Kaltenmeier C, Barth TF, Beyer T, Reister F, Fabricius D, Lotfi R, et al. Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res. 2013;73:2468-79. doi:10.1158/0008-5472.CAN-12-3450. PMID:23384943
29. Ma J, Ma D, Ji C. The role of IL-21 in hematological malignancies. Cytokine. 2011;56:133-9. doi:10.1016/j.cyto.2011.07.011. PMID:21824785
30. Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9 V delta 2 T cells for adoptive immunotherapy. J Immunol. 2009;182:3423-31. doi:10.4049/jimmunol.0803068. PMID:19265120
31. Eberl M, Engel R, Beck E, Jomaa H. Differentiation of human gamma-delta T cells towards distinct memory phenotypes. Cell Immunol. 2002;218:1-6. doi:10.1016/S0008-8749(02)00519-1. PMID:12470608
32. Caccamo N, Todaro M, La Manna MP, Sireci G, Stassi G, Dieli F. IL-21 regulates the differentiation of a human gammadelta T cell subset equipped with B cell helper activity. PLoS One. 2012;7:e41940. doi:10.1371/journal.pone.0041940. PMID:22848667
33. Bansal RR, Mackay CR, Moser B, Eberl M. IL-21 enhances the potential of human gammadelta T cells to provide B-cell help. European J Immunol. 2012;42:110-9. doi:10.1002/eji.201142017.
34. Gruenbacher G, Gander H, Rahm A, Idzko M, Nussbaumer O, Thurnher M. Ecto-ATPase CD39 inactivates Isoprenoid-Derived Vgamma9Vdelta2 T cell phosphoantigens. Cell Reports. 2016;16:444-56. doi:10.1016/j.celrep.2016.06.009. PMID:27346340
35. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangère V, Vincent J, Masson D, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity. 2012;36:362-73. doi:10.1016/j.immuni.2011.12.019. PMID:22406269
36. Ismaili J, Olislagers V, Poupot R, Fournie JJ, Goldman M. Human gamma delta T cells induce dendritic cell maturation. Clin Immunol. 2002;103:296-302. doi:10.1006/clim.2002.5218. PMID:12173304
37. Ni M, Martire D, Scotet E, Bonneville M, Sanchez F, Lafont V. Full restoration of Brucella-infected dendritic cell functionality through Vgamma9Vdelta2 T helper type 1 crosstalk. PLoS One. 2012;7:e43613. doi:10.1371/journal.pone.0043613. PMID:22928003
38. Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene. 2013;32:1743-51. doi:10.1038/onc.2012.269. PMID:22751118
39. Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF. CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression. Oncoimmunology. 2015;4:e1003015. doi:10.1080/2162402X.2014.1003015. PMID:26155397
40. Hu G, Wu P, Cheng P, Zhang Z, Wang Z, Yu X, Shao X, Wu D, Ye J, Zhang T, et al. Tumor-infiltrating CD39+gammadeltaTregs are novel immunosuppressive T cells in human colorectal cancer. Oncoimmunology. 2017;6:e1277305. doi:10.1080/2162402X.2016.1277305. PMID:28344891
41. Tosolini M, Pont F, Poupot M, Vergez F, Nicolau-Travers ML, Vermijlen D, Sarry JE, Dieli F, Fournié JJ. Assessment of tumor-infiltrating TCRVgamma9Vdelta2 gammadelta lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology. 2017;6:e1284723. doi:10.1080/2162402X.2017.1284723. PMID:28405516
42. Bastid J, Regairaz A, Bonnefoy N, Dejou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res. 2015;3:254-65. doi:10.1158/2326-6066.CIR-14-0018. PMID:25403716